Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000
Debt
Debt-to-Equity Ratio0.17
Current Ratio4.33
Quick Ratio3.28
Price-To-Earnings
Trailing P/E Ratio-4.82
Forward P/E Ratio-6.35
P/E GrowthN/A
Sales & Book Value
Annual Sales$93.47 million
Price / Sales5.91
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book5.66
Profitability
EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-100.09%
Return on Equity-95.29%
Return on Assets-60.07%
Miscellaneous
Employees456
Outstanding Shares131,940,000
Market Cap$580.54 million
Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions
What is Pacific Biosciences of California's stock symbol?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."
How were Pacific Biosciences of California's earnings last quarter?
Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.17). The biotechnology company had revenue of $21.58 million for the quarter, compared to analyst estimates of $24.45 million. Pacific Biosciences of California had a negative net margin of 100.09% and a negative return on equity of 95.29%. The firm's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History.
When is Pacific Biosciences of California's next earnings date?
What price target have analysts set for PACB?
4 analysts have issued 1 year price objectives for Pacific Biosciences of California's stock. Their predictions range from $3.80 to $6.80. On average, they expect Pacific Biosciences of California's share price to reach $4.90 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.
What is the consensus analysts' recommendation for Pacific Biosciences of California?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.
Who are some of Pacific Biosciences of California's key competitors?
Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).
Who are Pacific Biosciences of California's key executives?
Pacific Biosciences of California's management team includes the folowing people:
- Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
- Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
- Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
- Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
- Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)
Has Pacific Biosciences of California been receiving favorable news coverage?
Headlines about PACB stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a coverage optimism score of 0.11 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Pacific Biosciences of California.
Who are Pacific Biosciences of California's major shareholders?
Pacific Biosciences of California's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.31%), ARK Investment Management LLC (4.79%), Point72 Asset Management L.P. (2.20%), Frontier Capital Management Co. LLC (1.08%), Trellus Management Company LLC (0.53%) and Schwab Charles Investment Management Inc. (0.47%). View Institutional Ownership Trends for Pacific Biosciences of California.
Which major investors are selling Pacific Biosciences of California stock?
Which major investors are buying Pacific Biosciences of California stock?
PACB stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Point72 Asset Management L.P., Schwab Charles Investment Management Inc., Millennium Management LLC, Bank of New York Mellon Corp and Rhumbline Advisers. View Insider Buying and Selling for Pacific Biosciences of California.
How do I buy shares of Pacific Biosciences of California?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacific Biosciences of California's stock price today?
One share of PACB stock can currently be purchased for approximately $4.19.
How big of a company is Pacific Biosciences of California?
Pacific Biosciences of California has a market capitalization of $580.54 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.
How can I contact Pacific Biosciences of California?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]
MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.
